TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04993404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib Hydrochloride Tablets
Description: A single oral dose of 100 mg Jaktinib Hydrochloride Tablets will be administered.
Study: NCT06072885

Intervention type: OTHER
Intervention: Lung Ultrasound Scoring
Description: Pediatric Laparoscopic Surgery patients will be undergone Lung Ultrasound Scoring (LUS) at multiple times perioperatively. LUS is a pragmatic calculation reflecting lung aeration. Thorax is divided into 12 areas, and in every one of them LUS is applied to observe the lung condition. For that, if there are B-lines less than 4 in one area, it is scored as 1 point. For the areas containing more than 3 B-lines, it is scored as 2 points, and if there is any distortion on the pleural line, it is scored as 3 points. The areas with no B-lines is scored as 0 points. Considering these details, lungs with best conditions will reflect 0 points whereas the worst condition lungs will reflect 36 points. LUS will be performed after intubation, before extubation, and after 30th minute in the post anesthesia care unit
Study: NCT05706389

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ca-AKG
Description: Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Ca-AKG
Description: Eligible participants will be randomised to receive Ca-AKG or Placebo for 6 months.
Study: NCT05993637

Intervention type: OTHER
Intervention: Examination of propriception
Description: application of the tests used in proprioception assessment to patients by a physiotherapist

Intervention type: OTHER
Intervention: Examination of propriception
Description: application of the tests used in proprioception assessment to patients by a physiotherapist
Study: NCT04995146

Intervention type: OTHER
Intervention: Clinical stroke extended management pathway
Description: 1. Extracranial imaging~2. ECG in 2-7 days~3. DVT prophylaxis~4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management~5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent~6. Fasting lipid profile, HbA1c~7. Holter monitor~8. Specialized workup for young stroke~9. PFO Study, MES Study~10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team~11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography~12. Follow-up plan and 90 day mRS

Intervention type: OTHER
Intervention: Clinical stroke extended management pathway
Description: 1. Extracranial imaging~2. ECG in 2-7 days~3. DVT prophylaxis~4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management~5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent~6. Fasting lipid profile, HbA1c~7. Holter monitor~8. Specialized workup for young stroke~9. PFO Study, MES Study~10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team~11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography~12. Follow-up plan and 90 day mRS

Intervention type: OTHER
Intervention: Clinical stroke extended management pathway
Description: 1. Extracranial imaging~2. ECG in 2-7 days~3. DVT prophylaxis~4. Stroke educational material for patient and family Removal of Foley's catheter and start bladder management~5. Discharged on: Antithrombotic therapy OR Anticoagulation therapy▸ Antihypertensives ▸ Statins/cholesterol lower agent ▸ Antidiabetic agent~6. Fasting lipid profile, HbA1c~7. Holter monitor~8. Specialized workup for young stroke~9. PFO Study, MES Study~10. Referral to: ▸ Rehabilitation specialist ▸ Speech therapist ▸ Dietician ▸ Occupational therapist ▸ Medical team~11. Follow-up: CTA, CT angiography; HbA1c, glycated haemoglobin; MRA, MR angiography~12. Follow-up plan and 90 day mRS
Study: NCT05491993

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sky Medical™ Rapid Antigen Test
Description: Rapid Antigen Diagnostic Test device performance comparative to RT-PCR.
Study: NCT05578742

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEEP increase
Description: Positive End Expiratory Pressure (PEEP) will be increased from 5 to 15 cmH2O.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PEEP decrease
Description: Positive End Expiratory Pressure (PEEP) will be decreased from 15 to 5 cmH2O.
Study: NCT04433650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pictorial support in person-centred care for children (PicPecc)
Description: Phase A: The child has the protocol for methotrexate treatment, the healthcare professionals have one workshop that containing person-centred care, universal design, distress, symptom management and the digital reporting and communication tool.~Phase B: The child has everything in phase A. In addition, the child use the digital reporting and communication tool that has a thermometer (graded from zero (green) to ten (red)). The result of the assessment is visualized as a face (mimic and colour represents the intensity of the symptom and/or emotion (i.e., anxiety, appetite, fear/worries, how I´m feeling today, nausea, pain, sleep, and tiredness)). The digital reporting and communication tool has a body figure for location of pain, pictures for the type of pain, and an open question. There is an avatar and a gamification part, e.g., the child gets a pet after assessing the symptoms/emotions. The child reports in the app, and the child decides the frequency of assessments.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pictorial support in person-centred care for children (PicPecc)
Description: Phase A: The child has the protocol for methotrexate treatment, the healthcare professionals have one workshop that containing person-centred care, universal design, distress, symptom management and the digital reporting and communication tool.~Phase B: The child has everything in phase A. In addition, the child use the digital reporting and communication tool that has a thermometer (graded from zero (green) to ten (red)). The result of the assessment is visualized as a face (mimic and colour represents the intensity of the symptom and/or emotion (i.e., anxiety, appetite, fear/worries, how I´m feeling today, nausea, pain, sleep, and tiredness)). The digital reporting and communication tool has a body figure for location of pain, pictures for the type of pain, and an open question. There is an avatar and a gamification part, e.g., the child gets a pet after assessing the symptoms/emotions. The child reports in the app, and the child decides the frequency of assessments.
Study: NCT04938258

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Case Management
Description: Participants will receive an intensive Case Management (CM) intervention conducted by a multidisciplinary team (Psychiatry, Social Work, Nursing) during 2 months. The intervention will encompass attending weekly or biweekly appointments with the CM team, the interviews will last approximately 30 minutes. This CM intervention will include referral to Hospital Clínic de Barcelona Addiction Outpatient Clinic and a personalised assessment of the medical, psychiatric and social situation of each individual by the CM team. An individualised care plan will be established and periodically reviewed by the multidisciplinary team in response to a better understanding of patient needs or to a change in patient health condition. The intervention will offer motivational interviewing psychotherapy to enhance motivation to reduce or to quit alcohol use, in crisis intervention, coordination of care, patient education and self-management support, and assistance to navigate in the healthcare system.
Study: NCT05639972

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR-T cells
Description: Participants will receive a conditioning regimen consisting of cyclophosphamide and fludarabine. E7 TCR-T cells will be administered as a single intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Within 24 hours after E7 TCR-T cell infusion, aldesleukin 720,000 IU/kg IV will be administered every 8 hours as an inpatient for up to 3 doses. Aldesleukin dosing will be stopped for aldesleukin-related grade 3 or greater toxicity other than flushing, fever, chills, or hemodynamic changes (tachycardia or hypotension) that respond to crystalloid infusion. Aldesleukin may also be stopped at any time at investigator discretion.
Study: NCT05117775

Intervention type: OTHER
Intervention: No intervention - Just description and predictive models
Description: All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).

Intervention type: OTHER
Intervention: No intervention - Just description and predictive models
Description: All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).

Intervention type: OTHER
Intervention: No intervention - Just description and predictive models
Description: All the groups will be descriptive, there is not intervention, as it is an Observational study applying artificial Intelligence (RWE).
Study: NCT05294744

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: Day 1: 150 mg/kg in 250ml 5% glucose over 30min + 50mgr/kg in 500ml glucose over 4h + 100mgr/kg in 1000ml glucose over 16h intravenously.~Day 2-14: 100mgr/kg in 1000 ml glucose/24h intravenously. Day 15 until end of corticosteroid treatment: NAC 600mg orally every 24h.
Study: NCT06537115

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exercise
Description: progressive resistance exercise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exercise
Description: progressive resistance exercise

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: exercise
Description: progressive resistance exercise

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: whey protein powder
Description: The protein intake is 60 grams per day, taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: whey protein powder
Description: The protein intake is 60 grams per day, taken in three divided doses for 12 consecutive weeks. Attention should be paid to monitoring liver and kidney function, and the dosage of protein powder should be adjusted according to the condition of the patient.

Intervention type: DRUG
Group type: OTHER
Intervention: Eldecalcitol
Description: Eldecalcitol soft gel capsules are taken at an oral dose of 0.75μg once a day for 12 consecutive weeks.
Study: NCT05700695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branch Chain Amino Acid
Description: Intravenous branched chain amino acids will be given for 3 days to patients in experimental arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: Oral lactulose will be given to patients in both arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose
Description: Oral lactulose will be given to patients in both arms
Study: NCT05170711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypotensive anesthesia
Description: hypotensive anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: normotensive anesthesia
Description: normotensive anesthesia group
Study: NCT04822181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide administrated subcutaneously (under the skin) once weekly there will be a period of dose escalation before reaching the target dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administrated subcutaneously (under the skin) once weekly.
Study: NCT05317728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAL-FAIOL IOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject
Study: NCT06141278

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care cascade intervention
Description: Co-designed integrated care based on the Chronic Care Model to improve hypertension and diabetes care cascade
Study: NCT05105178

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giving orientation with headphones
Description: During emergence, recorded voice of an investigator giving Information of orientation (time, place, patient's own name) is repeatedly played from noise-cancelling headphones

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Emergence as usual with headphones
Description: During emergence, recorded voice of an investigator calling the patient's name is repeatedly played from noise-cancelling headphones
Study: NCT05970263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate (Breztri Aerosphere) 320 μg/18 μg/9.6 μg administered as two inhalations, twice daily.
Description: 2 inhalations twice daily administered by oral inhalation, from a metered dose inhaler, over a 12-month follow-up period.

Intervention type: OTHER
Group type: OTHER
Intervention: External Comparator
Description: Received any inhaled therapy, excluding triple inhaled maintenance therapy, during index hospitalization and refilled within 30 days before or after discharge from index hospitalization
Study: NCT05405283

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2nd booster with Comirnaty® (Pfizer-BioNTech)
Description: In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of Comirnaty® (Pfizer-BioNTech) vaccine as a second booster

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK
Description: In participants previously vaccinated with 3 doses of mRNA vaccine, he/she will receive one dose of CoV2 preS dTM adjuvanted vaccine (B.1.351), Sanofi/GSK vaccine as a second booster
Study: NCT05317728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAL-FAIOL IOL
Description: Investigational implantable medical device intended for long-term use over the lifetime of the cataract subject

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monofocal IOL
Description: Commercially available implantable medical device intended for long-term use over the lifetime of the cataract subject

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Phacoemulsification with a clear cornea incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cataract surgery
Description: Phacoemulsification with a clear cornea incision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Phacoemulsification with a clear cornea incision
Study: NCT06126237

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313, subcutaneous injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM313 injection
Description: CM313, subcutaneous injection
Study: NCT05099692

Intervention type: BEHAVIORAL
Intervention: filling out the questionnaire
Description: all participants in our study are invited to choose at least 1 question in 15 questions or provide their own questions regarding their doubt about the CR after filling in their personal information
Study: NCT05010356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Hyperinsulinemic euglycemic clamp

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Hyperinsulinemic euglycemic clamp
Study: NCT04949620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REThink therapeutic game
Description: REThink is a online therapeutic game developed by David and collaborators (2018), proved to be an efficient intervention for the reduction of emotional symptoms in children and adolescents.
Study: NCT06287034

Intervention type: PROCEDURE
Intervention: Primary suture
Description: The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)

Intervention type: PROCEDURE
Intervention: Primary suture
Description: The primary suture can be performed according to the different techniques available at the discretion of the surgeon (vertical, horizontal or T-shaped closure, with continuous suture, according to Connell or with detached stitches)
Study: NCT06130293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR game intervention
Description: Using self-paced VR game to train.
Study: NCT05682027

Intervention type: DIAGNOSTIC_TEST
Intervention: ultrasound of the diaphragm
Description: Parameters measured during ultrasound:~Thickening fraction; End-expiratory thickness, and; Diaphragm excursion.
Study: NCT04804189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guardians 4 Health
Description: Clubs will implement Guardians 4 Health's intervention into their community by (1) incorporating Guardians 4 Health materials into standard Club educational activities; (2) conducting a community- level Reframe event, led by Club adult and teen leaders; and (3) using social norms digital marketing materials.
Study: NCT04901910

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity (PA) Social Media Group
Description: Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities and well-being. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Verdi plus PA Social Media Group
Description: Participants will have access to the secret Social Media page that will deliver health information focused on increasing healthy activities, well-being, and reducing risky behaviors. This information will be posted by e-coaches. Participants can interact with the e-coaches as well as other study members in the group.
Study: NCT06461260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nervio-X
Description: An 8-channel TIS device developed by NEURODOME Corporation.
Study: NCT04864431

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D capsules: each capsule contain 2 tablets of vitamin D 1000 IU. One capsule will be taken on day 1 through 180

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule: Each capsule contain saccharum lactis. One capsule will be taken on day 1 through 180
Study: NCT05276479

Intervention type: OTHER
Intervention: Anonymous online survey on dietary habits and mental health
Description: Assessment of regular feeding behavior and mental health
Study: NCT05729412

Intervention type: OTHER
Intervention: Mentioned
Description: If prescription is properly filled for specific details than it is compliance

Intervention type: OTHER
Intervention: Mentioned
Description: If prescription is properly filled for specific details than it is compliance

Intervention type: OTHER
Intervention: Mentioned
Description: If prescription is properly filled for specific details than it is compliance
Study: NCT06273332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-assisted registration
Description: We will use artificial intelligence to register 3d model on intra-oral scan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Point-based registration
Description: We will use five references points or more to perform model registration
Study: NCT06410560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training about storytelling and creative writing: 12 hours
Description: Participants in training courses on creative writing and storytelling.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Training only about theoretical narrative medicine: 4 hours
Description: Participants in training courses on only theoretical narrative medicine.
Study: NCT04872114

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator
Description: Radiofrequency ablation of renal arterial sympathetic nerves
Study: NCT05402423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training plus aerobic exercise with the JDome System
Description: Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with the JDOME system,

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training plus aerobic exercise with standard exercise bike
Description: Sixteen treatment sessions of 60 minutes will be conducted (2 training sessions per week, for 8 weeks).~Each session will involve the following activities:~* 30 minutes of computerized cognitive training with the Brainer web platform, a medical device that contains 78 exercises in the five cognitive areas involved in the degeneration process of dementia~* 30 minutes of aerobic training with standard exercise bike